title: Synergistic effect of anti-platelet and anti-inflammation of drug-coated Co-Cr substrates for prevention of initial in-stent restenosis.
abstract: Antiplatelet and antithrombotic therapies are systematically considered to prevent restenosis following coronary stent implantation. Currently, patients receiving medicated stents are prescribed to orally take anticoagulants and antiplatelet drugs such as aspirin (ASP) and prasugrel (PRAS). Propolis (PROP) known as a natural organic compound was recently evaluated for its antiplatelet activity, antibiotics and immunomodulatory activities. In this study, antiplatelet drug-coated Co-Cr substrates were prepared with biodegradable poly(d,l-lactide) (PDLLA) containing ASP, PRA, or PROP using electrospray and the blood compatibility of the different substrates was investigated by measuring protein adsorption and platelet adhesion. In addition, the anti-inflammatory properties of the modified Co-Cr surfaces were assessed by measuring IL-8 and IL-6 expression levels in human endothelial cell cultures. Drug-coated surfaces were found to resist the adsorption of fibrinogen when compared to bare Co-Cr or PDLLA-coated Co-Cr. Interestingly, ASP- and PROP-containing substrates not only showed reduced adhesion of platelets and delayed coagulation time, but also drastically reduced the expression level of IL-8 and IL-6. Such results are supported that ASP- or PROP-coated Co-Cr can be potentially used as a stent material to mitigate early stage of restenosis. The developed coating materials might be an interesting alternative to systemic anticoagulant therapies prescribed after stent implantation.
authors.affiliation: Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
authors.forename: Eugene
authors.initials: E
authors.lastname: Lih
authors.affiliation: Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea; Department of Biomicrosystem Technology and Department of Chemical & Biological Engineering, Korea University, Seoul 02841, Republic of Korea.
authors.forename: Jee Won
authors.initials: JW
authors.lastname: Jung
authors.affiliation: Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea; Department of Biomedical Engineering, Korea University of Science and Technology, Daejeon 34113, Republic of Korea.
authors.forename: Yoon Ki
authors.initials: YK
authors.lastname: Joung
authors.affiliation: Department of Biomicrosystem Technology and Department of Chemical & Biological Engineering, Korea University, Seoul 02841, Republic of Korea; KU-KIST Graduate School of Converging Science & Engineering, Korea University, Seoul 02841, Republic of Korea.
authors.forename: Dong June
authors.initials: DJ
authors.lastname: Ahn
authors.affiliation: Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea; Department of Biomedical Engineering, Korea University of Science and Technology, Daejeon 34113, Republic of Korea. Electronic address: dkh@kist.re.kr.
authors.forename: Dong Keun
authors.initials: DK
authors.lastname: Han
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001241:Aspirin / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D002478:Cells, Cultured; D002858:Chromium Alloys / Q000737:chemistry; D003035:Cobalt / Q000737:chemistry; D023903:Coronary Restenosis / Q000517:prevention & control*; D065546:Drug Liberation; D004357:Drug Synergism; D054855:Drug-Eluting Stents; D006801:Humans; D008855:Microscopy, Electron, Scanning; D015539:Platelet Activation / Q000187:drug effects; D010973:Platelet Adhesiveness / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011091:Polyesters / Q000737:chemistry; D000068799:Prasugrel Hydrochloride / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D011429:Propolis / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D020123:Sirolimus / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D002858:Chromium Alloys; D010975:Platelet Aggregation Inhibitors; D011091:Polyesters; D003035:Cobalt; C033616:poly(lactide); D011429:Propolis; D000068799:Prasugrel Hydrochloride; D001241:Aspirin; D020123:Sirolimus
keywords: Anti-inflammation; Antiplatelet drug; Blood compatibility; Drug-eluting stent (DES); Surface coating